2French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int, 2006, 55( 1 ): 9-16.
3Paquet P, Pierard GE, Quatresooz P. Novel treatments for druginduced toxic epidermal necrolysis (Lyell's syndrome ). hat Arch Allergy Immunol, 2005, 136(3 ): 205-216.
4Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol, 2000, 115(2): 149-153.
5Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science, 1998, 282(5388): 490-493.
6Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Bums, 2007, 33(4): 452-459.
7Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129 ( 1 ): 92-96.
8Bastuji-Garin S, Fouchard N, Bertocehi M, et al. SCORTEN: a severity of illness score for toxic epidermal neerolysis. J Invest Dermatol, 2000, 115(2): 149-153.
9Imahara SD, Holmes JH, Heirnbaeh DM, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res, 2006, 27(3 ): 270-275.
10Cartotto R, Mayich M, Nickerson N, et al. SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Neerolysis Patients Treated in a Burn Center. J Bum Care Res, 2008, 29 (1): 141-146.
